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Virulence of a T6SS Campylobacter jejuni 
chicken isolate from North Romania
Vlad A. Ungureanu1, Alexandros Ch. Stratakos2,3, Ozan Gundogdu4, Lavinia Stef1, Ioan Pet1, Elena Pet5, 
Nicolae Pacala1 and Nicolae Corcionivoschi1,2*
Abstract 
Objectives: In this study we have investigated the in vitro and in vivo virulence characteristics of a new T6SS positive 
Campylobacter jejuni chicken isolate (SV12) originating from a poultry population in North Romania. A detailed pheno-
typic characterization was performed and compared to the T6SS negative C. jejuni 81–176 wild strain.
Results: Our results indicate that the significantly higher capacity to attach and invade HCT-8 cells of C. jejuni SV12 
isolate is associated with increased motility, increased resistance to bile salts and serum resistance, when compared 
to C. jejuni strain 81–76. Mice infected with the SV12 isolate showed statistically higher levels of colonization at both 
7- and 14-days post-inoculation and in the stomach, caecum, duodenum and large intestine. Infection with the SV12 
strain induced a stronger immune response as the gene transcript levels of IL-17, TNFα and IFNγ were more pro-
nouncedly up-regulated compared to the C. jejuni strain 81–176. The present study showed that the new isolate SV12 
had an enhanced virulence capacity compared to the wild strain which was evident in vivo as well. This work also 
provides an insight on the colonization pattern and host immune response differences between T6SS positive and 
T6SS negative C. jejuni.
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Introduction
Campylobacters are responsible for a wide range of ill-
nesses including diarrhoea, reactive arthritis and lead-
ing in some cases to serious neuromuscular syndromes 
such as Guillain-Barré [1]. In some instances, Campylo-
bacter spp., can produce and secrete toxins which can be 
transferred into eukaryotic [2] or prokaryotic cells. The 
transfer of these toxins can take place via the novel Type 
VI secretion system (T6SS), reported in Campylobacter 
recently [3, 4]. The identity component of the T6SS is the 
presence of the hcp gene [5]. The presence of this gene 
has been used to associate the T6SS system with severe 
infections in humans having as the most common symp-
toms bloody diarrhoea [6]. It has also been shown that 
the  hcp+ positive campylobacters display better adhesion 
and invasion properties in vivo [7, 8].
Campylobacter jejuni readily colonizes poultry within 
the first 12–14 days of life and is considered a commen-
sal with no disease phenotype and as consequence will 
not provide an insight into C. jejuni [9]. Mice would 
normally provide a preferred infection model system for 
pathogenic infection by C. jejuni especially if the aim is to 
investigate its colonization abilities only [10]. The aim of 
this study was to investigate the in vitro and in vivo viru-
lence capacity of a T6SS Campylobacter isolate (SV12). 
This isolate originates from the poultry populations in 
North Romania (Moldova).
Main text
Materials and methods
Bacterial strains and growth conditions and T6SS detection
Campylobacter jejuni strain (SV12) was isolated from 
caecal content broilers, conventionally housed raised in 
small family farms within the regions of Moldova, Roma-
nia. The isolate SV12 was retained and detected positive 
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for T6SS [11]. C. jejuni NCTC 12502 was used as the pos-
itive control. C. jejuni 81–176 was used as control strain 
in the infection assays.
In vivo infection assay
The infection assay was performed as previously 
described [12] using 5- to 6-week-old BALB/c mice 
(n = 10) with normal gut flora were purchased from 
Charles River Laboratories. All experiments were 
approved by the Animal Research Committee according 
to the legislation in place (Law 471/2002 and govern-
ment ordinance 437/2002) and under the supervision of 
National Sanitary Veterinary Agency. The ethics commit-
tee of Banat University of Agricultural Sciences and Vet-
erinary Medicine—King Michael I of Romania, approved 
this work.
Infection assays
The gentamicin protection assay was used to test the abil-
ity of C. jejuni SV12 chicken isolates to adhere and invade 
human intestinal epithelial cells using as control C. jejuni 
81–176 as previously described [6]. The experiments 
were conducted on three separate occasions. The signifi-
cance of differences in adhesion and invasion between 
samples was determined using the Student t test. A p 
value of < 0.05 was defined as significant.
Motility assays and serum resistance
In order to investigate the motility and serum resist-
ance of the SV12 isolate we have used methodologies 
previously published [6, 13]. The sensitivity of bacteria 
to human serum (Invitrogen) was measured by adding 5 
μl of bacterial suspension to duplicate wells of a six-well 
plate containing 800  μl of Mueller–Hinton broth and 
200  μl of active pooled human serum. All assays were 
conducted in triplicate and repeated independently three 
times.
Resistance to bile salts
The resistance to bile salts was investigated as previously 
described [14]. These experiments were done in tripli-
cates. Viable cell counts for each plate were determined 
at the end of the incubation period.
Antimicrobial resistance
The levels of antibiotic resistance for C. jejuni SV12 was 
tested by using nalidixic acid, ciprofloxacin, erythro-
mycin, ampicillin, amoxicillin-clavulanic acid and gen-
tamicin as previously described [14]. The test used was 
the disk E test from Solna, Sweeden.
RNA extraction and quantitative real‑time PCR
Tissue samples isolated from the infected or control 
mice were preserved in RNAlater at − 20 °C for later use. 
RNA was extracted using a Qiagen RNeasy kit (Qiagen) 
according to the manufacturer’s protocol. The primers 
used have been described previously described [15].
Statistical analysis
Experiments were conducted on at least three biological 
replicates. Results are presented as the means ± standard 
deviations (error bars) of three replicate experiments. 
Graphs were drawn using Prism, and the unpaired Stu-
dent t test was used to estimate statistical significance. A 
p value of < 0.05 was considered significant.
Results
In vitro virulence assay to test the virulence of the SV12 
isolate
The T6SS marker of SV12 isolate was detected as 
described in “Materials and methods” (data not shown) 
and its virulence aptitudes (invasion, adhesion) were con-
firmed using HCT-8 cells. Invasiveness varied between 
the investigated strain, as is shown in Fig. 1a (adhesion) 
and 1B (invasion). Following gentamicin protection assay 
we have shown that the total adhesion of the chicken iso-
late is significantly increased compared to the total adhe-
sion of C. jejuni 81–176. The C. jejuni chicken SV12 had 
higher levels of internalization compared to the C. jejuni 
81–176. Similarly, to the adhesion results, the chicken 
isolate SV12 had the highest internalization levels com-
pared to C. jejuni 81–176.
Investigation of SV12 bacterial motility and serum resistance
We have next investigated the role of motility, as viru-
lence factor, in the pathogenicity of the SV12 isolate. Our 
results show that its motility was significantly increased 
(4 cm, p < 0.001) when compared to the C. jejuni 81–176 
wild-type strain (2  cm) as observed in semisolid agar 
(See figure on next page.)
Fig. 1 Adhesion and invasion of the SV12 isolate. a Adhesion, b invasion of HCT-8 cells of C. jejuni 81–176 and C. jejuni SV12. Statistical significance 
(Student’s t test) relative to the level of C. jejuni 81–176 strain is indicated. The experiments were done in triplicate and on three separate occasions. 
The error bars represent standard deviations for six separate wells. c Motility of the C. jejuni chicken isolate SV12 and the C. jejuni 81–176 strain; d 
serum resistance is characterized as the number of C. jejuni colonies enumerated following exposure to human serum and divided by the number 
of colonies surviving to heat-inactivated serum (%) and e resistance to bile salts. Results are the mean of three separate experiments. Statistical 
significance (Student’s t test) relative to the level of C. jejuni 81–176 strain is indicated
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(Fig.  1c). The investigation of serum resistance abilities 
revealed that the survival rates of this new chicken iso-
late, SV12 are improved. As shown in Fig. 2b, the SV12 
isolate had a rate of survival of 78% (p < 0.001) compared 
to a survival rate of only 38% for C. jejuni 81–176. These 
results suggest that the increase in motility could account 
for the increase in the adhesion/invasion of this iso-
late (Fig.  1). Moreover, the increased rate of survival in 
human serum indicates the potential of C. jejuni SV12 to 
cause systemic infections.
In vitro resistance of SV12 isolate to bile salts
The ability to cope with the bactericidal activity of the 
bile is key for C. jejuni and to colonize the human or 
the animal gastrointestinal tract. We aimed to measure 
the response of C. jejuni 81–176 and SV12 isolate to the 
presence of bile salts in the culture media. The chicken 
isolates SV12 had significant (p < 0.01) better survival 
rate (65%) compared to only 55% survival rate of C. jejuni 
81–176 (Fig. 1d). Similar to the results observed for the 
survival to human serum and motility the resistance to 
bile salts also indicates a possible higher virulence apti-
tude for the SV12 isolate (Fig. 1e).
Antimicrobial resistance
For SV12 isolate and the control strain C. jejuni 81–176 
the antibiotic inhibition zones to the various antibiotics 
were investigated. The antibiotic profile of the C. jejuni 
Fig. 2 Motility, serum and bile resistance of C. jejuni SV12 isolate. For bacterial count determination of C. jejuni 81–176 and C. jejuni SV12 groups of 
12 mice were tested as described in “Materials and methods” a in the stomach, duodenum, large intestine and small intestine. RT-qPCR was used to 
investigate the cytokine production in the RNA extracted from the ceca of uninfected control or infected mice at 7- and 14-days post infection. b 
IL-17, c TNFα and d IFNγ. Statistical significance was determined using a student t test
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SV12 isolate was clearly different to C. jejuni 81–176 
which showed resistance only to gentamicin (Table  1). 
The chicken isolate SV12 was sensitive to all antibiotics 
except to amoxicillin–clavulanic acid.
In vivo colonization abilities of C. jejuni SV12 and immune 
response in infected mice
The in  vitro experiments suggested a higher virulence 
ability of the SV12 isolate. In order to get a better under-
standing, we have performed in  vivo mice infections to 
get a better insight on its pathogenicity. C. jejuni is usu-
ally detected in the large intestine and caecum in mice 
(n = 10) for each experimental group including the un-
infected control. In our experiments C. jejuni 81–176 
wild-type strain and the SV12 isolate were well able to 
colonize the stomach, duodenum, large intestine and 
small intestine (Fig.  2a). However, in all cases the mice 
infected with the SV12 isolate displayed higher and sta-
tistically significant levels at 7 days (p < 0.0001) and also 
at 14  days (p < 0.001) post-inoculation and in all com-
partments of the gut investigated (Fig.  2a). The higher 
colonization rates were associated with an increase in 
the immune response to infection. The investigation of 
gene transcript levels of IL-17 (Fig.  2b), TNFα (Fig.  2c) 
and IFNγ (Fig.  2d) suggested gut layer inflammation in 
infected mice as they showed upregulated gene transcript 
levels for all these three cytokines in mice infected with 
the SV12 isolate. All these elevated levels of cytokine 
release were statistically significant as described in Fig. 2.
Discussion
Motility allows Campylobacter to penetrate the mucus so 
it can adhere to and invade surface epithelial cells [14]. In 
this study, the motility of the C. jejuni isolate SV12 and C. 
jejuni 81–176 wild-type strain was determined and com-
pared. SV12 showed significantly higher motility which 
was also consistent with a higher attachment capacity 
exhibited compared to C. jejuni 81–176 wild-type strain. 
Differences in motility are of great importance during 
infection and can influence the pathogen’s ability to cause 
disease.
SV12 also showed significantly higher internalization 
in HCT-8 cells. Cell adhesion and invasion are critical 
for gut pathogens to exert their pathogenic potential and 
establishing persistence. Recent studies on E. coli suggest 
that T6SS promotes host cell adhesion and invasion, the 
two fundamental steps required for host colonization 
and the attainment of full virulence [16]. It is possible 
that C. jejuni hcp possibly serves as a structural protein 
that can facilitate host cell adhesion as well as an effec-
tor that can promote host cell invasion [7]. Therefore, the 
higher adhesion and invasion levels observed here could 
be attributed to the fact that SV12 harbours a functional 
T6SS system. C. jejuni must be able to withstand the bile 
salts secreted into the intestinal tract and the bactericidal 
effects of the human and animal serum in order to cause 
infection [17]. In the present study, although both strains 
were susceptible to bile salts, SV12 showed increased 
survival compared to the C. jejuni 81–176 control strain. 
The same trend was also evident when both strains were 
exposed to human serum.
Campylobacter can acquire antimicrobial resistance 
genes via horizontal gene transfer, acquisition of mobile 
genetic elements and mutations. Treatment of severe 
infection occasionally necessitates antimicrobial therapy. 
Although fluoroquinolones were regularly used in the 
past to fight the infection, the rising of resistance among 
Campylobacter isolates has rendered these antibiot-
ics ineffective and now erythromycin is the antibiotic of 
choice [18]. The present study showed that the SV12 was 
more resistant to nalidixic acid, ciprofloxacin, erythro-
mycin, and ampicillin compared to the wild strain. The 
study of According to Lluque et  al. there is an increas-
ing trend in macrolide resistance quinolones resistance, 
among C. jejuni. Stressing the need of new antimicrobial 
agents to treat infections cause by this pathogen [19].
The above results show that the C. jejuni chicken iso-
late SV12 exhibits an enhanced range of virulence pheno-
types in vitro compared to the wild strain. Nevertheless, 
extrapolating these results to the host should be done 
with caution as the host’s susceptibility plays an impor-
tant role in C. jejuni infection [20]. In order to confirm 
the increased virulence potential of C. jejuni SV12 an 
in  vivo infection using a mouse model was also per-
formed. The results revealed that C. jejuni multiplied in 
the intestines of mice. The caecum and the duodenum 
having the highest levels of C. jejuni both after 7- and 
14-days post inoculation. Although both C. jejuni iso-
lates used in this study were able to colonise the intestine, 
their ability to colonize the intestines varied. The strain 
Table 1 Antimicrobial resistance rates of C. jejuni isolated from poultry
Isolate Nalidixic acid Ciprofloxacin Erythromycin Ampicillin Amoxicillin–
clavulanic acid
Gentamicin
C. jejuni 81–176 − − − − − +
SV12 + + + + − +
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which was more virulent based on the results of the 
in vitro studies (SV12) showed higher levels in the stom-
ach, duodenum, caecum and large intestine compared to 
the wild strain.
The cytokine profile was also determined in order 
to investigate the host immune response to the two C. 
jejuni strains. The results revealed that C. jejuni infec-
tion resulted in up-regulation of IL17, TNFα and IFNγ 
mRNA expression. Mice infection with a human and 
food C. jejuni isolates induced strong pro-inflammatory 
responses with elevated levels of IL-12, TNF-α and IFN-
γ. Cytokine IL-17 has also been found to increase in the 
intestines of C. jejuni infected mice [21, 22]. The results 
here show that host immune response to C. jejuni differs 
between hcp positive and hcp negative strains, with the 
hcp positive strain inducing a stronger immune response.
Limitations
The study has one major limitation it did not include 
additional C. jejuni strains. The inclusion of more poul-
try isolates, both T6SS positive and T6SS negative, would 
allow to further confirm the in  vitro and in  vivo differ-
ences in virulence, observed.
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